Comparing topical and injection treatment for hidradenitis suppurativa
Part of Infections, Skin clinical trials.
This study tests whether applying secukinumab as a topical cream or as a subcutaneous injection is more effective and safer for treating hidradenitis suppurativa (a skin condition causing painful lumps). It aims to find a better way to manage symptoms in people whose condition has not improved with standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have a diagnosis of hidradenitis suppurativa (HS) for at least 6 months.
- Your HS must not have improved significantly after at least 3 months of standard treatment.
- Your HS lesions must be in just one area of the body.
- You cannot have used certain biologic drugs, immunosuppressants, or systemic corticosteroids in the last 3 months.
- You cannot be pregnant, nursing, or planning to become pregnant during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether combining the drug secukinumab with surgery can help people with moderate to severe hidradenitis suppurativa (HS). It looks at how well this combination works and if it is safe over a year.
This study tests a drug called secukinumab (a type of biologic that targets inflammation) for people with moderate to severe hidradenitis suppurativa (HS). It may be an option if you have tried other treatments and they didn't work well.
This study tests if a drug called secukinumab (a self-injected biologic) is safe and effective for adults with moderate-to-severe hidradenitis suppurativa (HS) in China. It may help reduce the number of painful HS lesions.
This study looks at certain immune cells (called MAIT cells) in the skin of people with hidradenitis suppurativa, a painful skin condition. It will compare samples from people before they start a new biologic treatment, and may help doctors understand how these treatments work.
This trial tests a new medicine called SCT650C for people with moderate to severe hidradenitis suppurativa (HS). The goal is to see if it can reduce painful bumps and abscesses better than current treatments.
This study tests a new injected medication (SPY072) for people with moderate to severe hidradenitis suppurativa (HS), a condition causing painful bumps and abscesses. The goal is to see if this treatment can reduce symptoms and improve quality of life.
Hear when a new Hidradenitis Suppurativa (Acne Inversa) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.